While neoadjuvant HER2-targeted therapy with chemotherapy remains the current standard of care for locally advanced HER2+ breast cancer, oncologists may be overtreating a significant proportion of patients who could achieve the same outcomes without chemotherapy. Here, ERBB2 is linked to breast carcinoma.